History 0 7 0 7 O
of 8 10 8 10 O
anaphylaxis 11 22 11 22 B-chronic_disease
to 23 25 23 25 O
cat 26 29 26 29 B-allergy_name
allergen 30 38 30 38 I-allergy_name

History 0 7 39 46 O
of 8 10 47 49 O
dermatographia 11 25 50 64 B-chronic_disease

History 0 7 65 72 O
of 8 10 73 75 O
intubation 11 21 76 86 B-treatment
for 22 25 87 90 O
asthma 26 32 91 97 B-chronic_disease
exacerbation 33 45 98 110 I-chronic_disease

Immunotherapy 0 13 111 124 B-treatment
with 14 18 125 129 O
cat 19 22 130 133 O
or 23 25 134 136 O
dust 26 30 137 141 O
mite 31 35 142 146 O
extract 36 43 147 154 O
now 44 47 155 158 O
or 48 50 159 161 O
in 51 53 162 164 O
the 54 57 165 168 O
past 58 62 169 173 B-upper_bound
5 63 64 174 175 I-upper_bound
years 65 70 176 181 I-upper_bound

Negative 0 8 182 190 O
skin 9 13 191 195 O
test 14 18 196 200 O
to 19 21 201 203 O
panel 22 27 204 209 O
of 28 30 210 212 O
12 31 33 213 215 O
allergens 34 43 216 225 O
, 43 44 225 226 O
including 45 54 227 236 O
dust 55 59 237 241 B-allergy_name
mite 60 64 242 246 I-allergy_name
and 65 68 247 250 O
cat 69 72 251 254 B-allergy_name
allergen 73 81 255 263 O

Other 0 5 264 269 O
lung 6 10 270 274 B-chronic_disease
diseases 11 19 275 283 I-chronic_disease
, 19 20 283 284 O
such 21 25 285 289 O
as 26 28 290 292 O
sarcoidosis 29 40 293 304 B-chronic_disease
, 40 41 304 305 O
bronchiectasis 42 56 306 320 B-chronic_disease
or 57 59 321 323 O
active 60 66 324 330 O
lung 67 71 331 335 O
infection 72 81 336 345 I-chronic_disease

Participation 0 13 346 359 O
in 14 16 360 362 O
another 17 24 363 370 O
research 25 33 371 379 O
study 34 39 380 385 O
involving 40 49 386 395 O
a 50 51 396 397 O
drug 52 56 398 402 O
or 57 59 403 405 O
biologic 60 68 406 414 O
during 69 75 415 421 O
the 76 79 422 425 O
past 80 84 426 430 B-upper_bound
30 85 87 431 433 I-upper_bound
days 88 92 434 438 I-upper_bound

Presence 0 8 439 447 O
of 9 11 448 450 O
past 12 16 451 455 O
or 17 19 456 458 O
current 20 27 459 466 O
medical 28 35 467 474 B-chronic_disease
problems 36 44 475 483 I-chronic_disease
/ 44 45 483 484 O
other 45 50 484 489 O
factors 51 58 490 497 O
that 59 63 498 502 O
may 64 67 503 506 O
pose 68 72 507 511 O
additional 73 83 512 522 O
risks 84 89 523 528 O
from 90 94 529 533 O
participation 95 108 534 547 O
or 109 111 548 550 O
influence 112 121 551 560 O
study 122 127 561 566 O
results 128 135 567 574 O
, 135 136 574 575 O
as 137 139 576 578 O
determined 140 150 579 589 O
per 151 154 590 593 O
study 155 160 594 599 O
investigator 161 173 600 612 O

Use 0 3 613 616 O
of 4 6 617 619 O
Xolair 7 13 620 626 B-treatment
( 14 15 627 628 I-treatment
omalizumab 15 25 628 638 I-treatment
) 25 26 638 639 I-treatment
within 27 33 640 646 O
the 34 37 647 650 O
last 38 42 651 655 B-upper_bound
6 43 44 656 657 I-upper_bound
months 45 51 658 664 I-upper_bound

â‰¥ 0 1 665 666 O
10 2 4 667 669 B-lower_bound
pack 5 9 670 674 O
- 9 10 674 675 O
years 10 15 675 680 O
smoking 16 23 681 688 O
or 24 26 689 691 O
any 27 30 692 695 O
smoking 31 38 696 703 O
in 39 41 704 706 O
the 42 45 707 710 O
past 46 50 711 715 O
year 51 55 716 720 O

